Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

13. Quarterly Financial Data (Unaudited)

The following is a summary of the quarterly consolidated results of operations for the years ended December 31, 2013 and December 31, 2012:

	For the Quarter Ended
	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Revenues	$	1,367,472		$	1,613,262		$	1,635,600		$	3,871,632
Loss from Operations		(7,447,515	)		(6,776,618	)		(5,856,468	)		(2,996,158	)
Net Income (Loss)		(10,787,148	)		(3,886,421	)		(4,610,961	)		(844,754	)
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(9,764,323	)		(3,042,111	)		(4,091,196	)		(365,247	)
Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.22	)	$	(0.07	)	$	(0.09	)	$	(0.01	)
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.22	)	$	(0.07	)	$	(0.09	)	$	(0.01	)
Weighted Average Shares Outstanding, Basic		44,826,576			44,948,591			45,061,274			45,170,129
Weighted Average Shares Outstanding, Diluted		44,826,576			44,948,591			45,061,274			45,170,129

	For the Quarter Ended
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Revenues	$	931,397		$	258,237		$	219,575		$	2,161,501
Loss from Operations		(7,481,875	)		(9,161,724	)		(7,841,541	)		(5,561,466	)
Net Income (Loss)		(6,398,894	)		(5,906,870	)		(12,315,676	)		2,206,800
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(5,387,146	)		(5,078,684	)		(10,877,836	)		3,109,524
Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
Weighted Average Shares Outstanding, Basic		35,657,563			35,745,675			35,879,245			42,236,226
Weighted Average Shares Outstanding, Diluted		35,657,563			35,745,675			35,879,245			42,565,945